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Abstract Lysophosphatidylcholine (lyso-PC) accumulates in
tissues undergoing inflammation and atherosclerosis, where an
infiltration of T cells is also seen. We found that lyso-PC
increased IFN-Q production and CD40L expression in CD4+ T
cells stimulated with anti-CD3 Ab and recombinant CD80
molecules, whereas lyso-PC did not affect IL-2 and IL-4
production. These results suggest that lyso-PC, in combination
with other stimuli, may regulate CD4+ T cell functions to
propagate local inflammatory reactions and also imply a novel
role played by a modified lipid in the selection of Th1/Th2
immune response as well as in the T cell mediated pathogenesis in
atherosclerosis.
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1. Introduction
Tissue in¢ltrating T cells are involved in the pathogenesis of
such disorders as autoimmunity, in£ammation, and infection.
Among the in¢ltrating T cells, CD4+ T cells are important in
the sense that they not only recognize class II restricted anti-
gen but also regulate immune response by secreting various
lymphokines [1]. In non-classical immune disorders, such as
degenerative vascular disorders, CD4+ T cells are also indi-
cated to play indispensable roles [2]. For instance, CD4+ T
cell depletion by an anti-CD4 monoclonal antibody reduces
post-angioplasty arteriosclerosis in rats by inhibiting the ac-
cumulation of mononuclear and smooth muscle cells in the
intima of the arterial wall [3], and also reduces the incidence
of spontaneous atherosclerosis in hyperlipidemic mice [4]. In
the animal model of post-transplantation arteriosclerosis, the
blockade of CD28/CD80 mediated T cell stimulation signi¢-
cantly reduced the frequency and severity of arteriosclerosis
[5]. Thus, these results indicate that the activated T cells in-
¢ltrating the lesion are directly involved in the pathogenesis of
these vascular disorders.
The atherosclerotic lesion also sees the accumulation of
modi¢ed lipids such as ox-LDL [6] and lysophosphatidylcho-
line (lyso-PC) [7]. However, it is still unknown how the in-
crease of modi¢ed lipids in the tissue a¡ects the function of
the T cells in¢ltrating the same tissue. T cells are primarily
activated by antigens and costimulation molecules to secrete
lymphokines and to express various cell surface molecules. In
the milieu, where T cells are activated by antigen presenting
cells, the concomitant presence of bioactive lipids may alter
the function of those T cells. Considering this, we assessed the
e¡ect of lyso-PC, a major phospholipid produced in tissue
undergoing infection, in£ammation, and atherosclerosis, on
the function of the CD4+ T cells which were stimulated
through the TCR/CD3 complex and costimulation receptor
CD28.
CD40L/CD40 interaction was originally described as regu-
lating B cell growth and di¡erentiation. Stimulation through
CD40 augments tumoricidal activity and cytokine production
in monocytes and increases antigen presentation by dendritic
cells [8]. Recent literature on CD40 includes the control of
expression of cell adhesion molecules [9], production of cyto-
kines [10] and matrix degrading enzymes [11] in the EC and
SMC in the vascular walls. Here we show the evidence that
lyso-PC may enhance the in£ammatory response by increasing
interferon gamma (IFN-Q) production and CD40 ligand
(CD40L) expression in newly activated CD4+ T cells, which
could indicate a novel role played by lyso-PC and T cells in
the in£ammatory aspects of atherogenesis and tissue remodel-
ing in the vascular walls [12].
2. Materials and methods
2.1. LCD32 cells expressing CD80 molecule and cell culture conditions
L cells coexpressing the CD80 and the CD32 molecules were pre-
pared following the method described previously [13]. First, cDNA
including the whole coding region of CD80 was obtained by RT-PCR
ampli¢cation of mRNA extracted from EBV-transformed peripheral
B cells using speci¢c primer pairs: sense CCTAAGCATCTGAAGC-
CATG, and antisense GATGGCAGAATGGAAACATG. Next, the
ampli¢ed product was cloned into the pCRIII expression vector (In-
vitrogen) and sequenced. Plasmid DNA from one such clone was
transfected with lipofectin (Gibco-BRL, Gaithersbug, MD) into
LCD32 cells expressing the FcQII receptor CD32 [14]. The cells were
grown in medium containing 400 Wg/ml G418 (Life Technology) and
HAT (Gibco, Grand Island, NY) to select the stably transfected
LCD32 cells. Finally, stable transfectants were screened ¢rst for their
expression of CD80 using an anti-CD80 Ab (Serotec) and PE-conju-
gated goat anti-mouse IgG (Caltag), and second for their ability to
costimulate T cells pretreated with anti-CD3 Ab using a proliferation
assay. The most potent cell line was recloned and designated LCD32/
CD80 and used in this study. To control the e¡ect of G418 in the
culture, we transfected pCRIII-neo plasmid to LCD32 cells (LCD32/
neo). Wild type L cells (Lwt), LCD32/neo and LCD32/CD80 cells
were cultured in RPMI 1640 (Gibco, Grand Island, NY) supple-
mented with 10% FCS (Bio Whittaker), 50 WM 2-mercaptoethanol,
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5% NCTC109 (Gibco, Grand Island, NY), 100 U/ml penicillin and
100 Wg/ml streptomycin. HAT and G418 were added to the medium
for the LCD32/neo and LCD32/CD80 cells.
2.2. CD4+ T cells preparation
T cells were puri¢ed from the peripheral blood of healthy donors by
E-rosette followed by a Ficoll-Conray method as described elsewhere
[15]. CD4+ T were puri¢ed by positive selection using a MACS beads
cell separation system (Miltenyi Biotec, Sunnyvale, CA). The purity
was usually over 90%, which was estimated by £ow cytometric anal-
ysis using FITC conjugated anti-CD4 (Nu-TH=I, Nichirei, Japan) and
PE conjugated anti-CD8 (Nu-TS=C, Nichirei, Japan).
2.3. Coculture system
For proliferation assays and cytokine analysis, 5U104 T cells and
1U104 L cells irradiated at 7000 rad were cocultured in 200 Wl of
RPMI 1640 with 5% FCS. A graded dose of anti-CD3 Ab (ATCC
CRL-8001) and lyso-PC (palmitoyl, C16:0, Avanti, Alabaster, AL)
were added to the medium. For £ow cytometric analysis, 2.5U105
T cells and 5U104 L cells were cocultured in 1 ml of medium con-
taining 1 Wg/ml of anti-CD3 Ab and the indicated amount of lyso-PC.
For Northern blot analysis, 5U106 T cells and 1U106 L cells were
cocultured in 10 ml of medium containing 1 Wg/ml of anti-CD3 Ab
and the indicated amount of lyso-PC.
2.4. Proliferation assay
T cells were cocultured with L cells in £at bottomed 96 well plates
(Corning, New York) for 60 h in which the mitogenic e¡ect by an
anti-CD3 Ab and a reproducible e¡ect by lyso-PC were best seen.
During the last 10 h of culture, 10 WCi [3H]TdR (Amersham, Buck-
inghamshire, UK) was added to each well; incorporated 3H was
measured by a scintillation counter (Top counter, Hewlett-Packard).
Cell viability was assessed by trypan blue exclusion at the end of
culture. The indicated amount of anti-CD3 Ab and lyso-PC were
added to the medium at the start of the coculture.
2.5. Cytokine assay
The supernatants were collected after 36 h of coculture. Interleukin-
2 (IL-2) was measured using the CTLL-2 cell line (ATCC, TIB 214) as
described elsewhere [16]. IL-4 was measured by proliferation assay
using the CT-h4S cell line which expresses the human IL-4 receptor
(kindly provided by Dr. William Paul, Laboratory of Immunology,
NIAID/NIH) [17]. The detection limit for the IL-4 in this assay was
10 pg/ml. IFN-Q was quantitated by enzyme linked immunosorbent
assays (ELISAs) using mouse anti-human IFN-Q (Genzyme) as cap-
ture mAb, biotinylated mouse anti-human IFN-Q (Bender MedSys-
tems) and alkaliphosphatase labeled mouse anti-biotin (Zymed) as
detection antibodies in 96 well assay plates (Nunc Immuno Plate
MaxiSorp). The detection limit for the IFN-Q assay was 1 ng/ml. To
control each assay, we used recombinant human IL-2 (Takeda Phar-
maceutical Co., Japan), recombinant human IL-4 (Ono Pharmaceut-
ical Co., Japan) and recombinant human IFN-Q (Ootsuka Pharma-
ceutical Co., Japan).
2.6. Flow cytometric analysis
T cells were stained with optimally diluted PE conjugated mouse
anti-human CD2 (Nu-TER, Nichirei, Japan), biotin conjugated mouse
anti-human CD40L (Ancell Corporation), and FITC conjugated anti-
CD11a (LFA-1) (Caltag Laboratories). For detection of CD40L, the
samples were further incubated with avidin conjugated FITC (Phar-
mingen). Finally, propidium iodide (PI) was added to each cell sus-
pension so that the gates could be set to exclude dead cells. Surface
immuno£uorescence was assessed using a £ow-cytometer (EPICS XL,
Coulter Electronics, Hialeah, FL).
2.7. Northern blot analysis
Northern blot analysis of the CD40L mRNA was performed by a
standard method utilizing total RNA isolated from CD4+ T cells
cocultured. RNA separated in 0.7% agarose gel were transferred
onto a Biodyne nylon membrane and hybridized with random labeled
cDNA probes of CD40L (residues 391^831) and L-actin (Clontech,
Palo Alto, CA). Jurkat cells [18] and EBV transformed B cell line
(EBLB) were used as positive and negative controls, respectively.
2.8. Statistic analysis
Statistic analysis was done using Student’s t-test.
3. Results
3.1. Coculture with LCD32/CD80 cells augments proliferation
of T cells stimulated with anti-CD3
In our initial experiment, we created cell lines to stimulate T
cells through CD3 and a costimulation receptor, CD28. The
dual expression of CD32 and CD80 molecules in LCD32/
CD80 cells was con¢rmed by £ow cytometric analysis (Fig.
1A) and proliferation assay using peripheral T cells (Fig. 1B).
As previously reported [14], T cells are activated with a CD3
receptor being cross-linked by an anti-CD3 Ab of which the
Fc portion binds to CD32 molecules expressed on LCD32/neo
and LCD32/CD80. There was no such mitogenic e¡ect by
anti-CD3 in the coculture with Lwt cells which do not express
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Fig. 1. A: The expression of CD80 in LCD32/neo and LCD32/CD80. B: CD80 molecules expressed on the LCD32/CD80 cells augment anti-
CD3 mediated cell proliferation in CD4+ T cells. CD4+ T cells were cocultured with LCD32/neo and LCD32/CD80 in the medium containing
anti-CD3 Ab (a, 0 Wg/ml; b, 0.01 Wg/ml; R, 1 Wg/ml) and the indicated amount of lyso-PC. Cell proliferation at 60 h (C), IL-2 (D), IFN-Q
(E) and IL-4 (F) secretion at 36 h are shown. Results are expressed as the mean þ S.E.M. (*P6 0.01).
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CD32 molecules. Coculture of T cells with LCD32/CD80 aug-
mented a mitogenic e¡ect by anti-CD3 Ab (Fig. 1B), which
was explained by the greater amount of IL-2 production [19]
with LCD32/CD80 than with LCD32/neo (Fig. 1D). Thus,
costimulation by CD80 molecules, expressed on the LCD32/
CD80 cell, was synergistic to CD3 cross linking, and resulted
in an enhanced proliferation of T cells.
3.2. E¡ect of lyso-PC on the proliferation and lymphokine
production by CD4+ T cells
Addition of lyso-PC to the culture medium did not lead to
signi¢cant change in cell proliferation and IL-2 production in
the coculture either with LCD32/neo or with LCD32/CD80
(Fig. 1C,D). Anti-CD3 stimulation alone induced a minimum
level of IFN-Q production, however lyso-PC did not a¡ect
IFN-Q production in this culture (Fig. 1E). In contrast, coin-
cubation with 10 WM lyso-PC signi¢cantly augmented the
IFN-Q production of CD4+ T cells cultured with LCD32/
CD80 in the presence of anti-CD3 (Fig. 1E) (P6 0.01).
Lyso-PC induced dose dependent increases of IFN-Q up to
50 WM (data not shown), however, this e¡ect was not seen at
100 WM of lyso-PC because of the detergent e¡ect of lyso-PC
at this concentration. In IL-4 production, costimulation by a
CD80 molecule augmented IL-4 production in anti-CD3
stimulated CD4+ T cells (Fig. 1F). The presence of lyso-PC
in the medium did not show signi¢cant e¡ects on IL-4 pro-
duction. Thus, lyso-PC per se did not have an induction e¡ect
on IFN-Q production, however, lyso-PC did have a synergistic
e¡ect on anti-CD3 stimulation in IFN-Q production when
costimulation by CD80 was provided.
3.3. E¡ects of lyso-PC on CD2 and CD40L expression in the
activated CD4+ T cells
Having obtained evidence that lyso-PC modi¢es the e¡ect
of anti-CD3 and CD80 stimulation in cytokine production, we
next studied the e¡ect of lyso-PC on the expression of a co-
stimulation ligand CD40L in CD4+ T cells. In this study,
CD4+ T cells were activated with three di¡erent L cells
(Lwt, LCD32/neo, LCD32/CD80) in the presence of anti-
CD3 (1 Wg/ml) and lyso-PC in the medium for 60 h. Anti-
CD3 stimulation induced the emergence of CD2bright/
CD40Lhigh cells (Fig. 2A b) and we could discern three pop-
ulations in CD2 positive cells: CD2dull, CD2medium, and
CD2bright cells. The addition of CD80 costimulation further
increased the population of CD2bright/CD40Lhigh cells (Fig. 2A
c). In the coculture with LCD32/neo and LCD32/CD80, ad-
dition of lyso-PC increased the percentage of CD40Lhigh cells
in CD2bright cells (Fig. 2A d, Fig. 2B). In the time-course
study, the presence of lyso-PC in the coculture medium facili-
tated the appearance of CD2bright/CD40Lhigh cells at an earlier
time point than in the coculture without lyso-PC (data not
shown). To con¢rm upregulation of CD40L molecules by
lyso-PC, we did a Northern blot analysis. This clearly indi-
cated that upregulation of CD40L molecules was associated
with an increase of their mRNA level. In the coculture of
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Fig. 3. Northern blot analysis of CD40L expression in CD4+ T
cells. A: The dose response of CD40L mRNA synthesis to the con-
centration of lyso-PC (0, 1, 30 WM) by the CD4+ T cells cocultured
with LCD32/CD80 in the presence of anti-CD3 (1 Wg/ml). B: The
time course of CD40L mRNA synthesis by the CD4+ T cells cocul-
tured with LCD32/CD80 in the presence of anti-CD3 (1 Wg/ml) and
lyso-PC (30 WM). CD4+ T cells were cocultured with indicated L
cells. Stimulation was done using anti-CD3 Ab (1 Wg/ml) and lyso-
PC (0, 30 WM) for 48 h. C: Density plots of CD40L mRNA signals
normalized with L-actin signals (*P6 0.01, **P6 0.05).
Fig. 2. A: Flow cytometric analysis of CD2 and CD40L expression
in CD4+ T cells cocultured with Lwt, LCD32/neo, and LCD32/
CD80 for 60 h in the medium containing anti-CD3 (1 Wg/ml) and
lyso-PC. Puri¢ed CD4+ T cells before stimulation (a), cocultured
with LCD32/neo (b) and LCD32/CD80 (c). Lyso-PC (30 WM) was
added to the medium of coculture with LCD32/CD80 (d). B: The
percentage of CD2bright and CD40Lhigh cells (in region R1) in
CD4+ T cells cocultured with indicated L cells and anti-CD3 (1 Wg/
ml) vs. dose of lyso-PC in the medium (*P6 0.01, **P6 0.05).
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CD4+ T cells with LCD32/neo and LCD32/CD80, the pres-
ence of 30 WM lyso-PC in the medium augmented the increase
of CD40L mRNA level which was induced by anti-CD3 treat-
ment (Fig. 3A,C). This e¡ect by lyso-PC was dose dependent
(Fig. 3A), and the maximal e¡ect was seen at 48 h of coincu-
bation (Fig. 3B). Thus lyso-PC stimulation was synergistic to
the stimulus provided by anti-CD3 in the upregulation of
CD40L at mRNA level.
We next studied the e¡ect of lyso-PC on the expression of
CD11a (LFA-1). Lyso-PC did not augment the expression of
CD11a in CD4+ T cells stimulated with anti-CD3 alone (Fig.
4B). However, with costimulation by CD80 in addition to
anti-CD3 stimulation, we did see an increase of the CD11a
expression in the lyso-PC treated CD4+ T cells (Fig. 4A,B).
4. Discussion
In lymphoid organs, T cells are primarily activated by stim-
uli provided by antigens, cytokines and various cell adhesion
molecules. The requirements of costimulation [20] and cyto-
kine stimulation [1] in T cell activation and di¡erentiation are
well documented. In non-lymphoid organs, such as vascular
walls and intestinal walls, activation and functional di¡eren-
tiation of tissue in¢ltrating T cells are also a¡ected by a mi-
croenvironment containing lipid derived bioactive mediators
[21] or bacteria derived lipopolysaccharides [22] which are
known to regulate T cell function.
Lyso-PC is catabolized from phosphatidylcholine by the
secreted phospholipase A2 (PLA2) [7] or by a free radical
reaction [6] in tissue with on-going in£ammation [23] and
atherosclerotic lesions [24]. In physiological circumstances, T
cells are mostly stimulated by the antigen presenting cells
which are endowed with various costimulation molecules,
most notably CD80/86. Recently the involvement of PLA2
in the CD80/86-CD28 signaling cascade has been demon-
strated [25]. These data led us to study the lyso-PC e¡ect on
T cells activated by stimuli through a CD28 receptor in con-
junction with CD3 receptors.
First, we showed that lyso-PC caused an augmentation of
IFN-Q secretion (Fig. 1E) and upregulation of CD40L (Fig. 2)
and CD11a expression (Fig. 4) in CD4+ T cells stimulated
with anti-CD3 and CD80. Anti-CD3 and anti-CD3/CD80
stimuli were essential in these experiments, since lyso-PC stim-
ulation alone is not potent enough to induce IFN-Q secretion
and CD40L/CD11a upregulation.
Our results showed that lyso-PC su⁄ciently coactivates
anti-CD3 stimulated CD4+ T cells in CD40L upregulation
(Fig. 2), however, it requires CD80 stimulation for optimal
IFN-Q production (Fig. 1) and CD11a upregulation (Fig. 4).
This di¡erent requirement of CD80 stimulation could be ex-
plained in part by the fact that lyso-PC activates JNK [26],
which is also activated by the CD28-CD80 costimulatory sig-
nal [20,27]. Thus lyso-PC stimulation transduces signals which
partly converge to the stimulation conveyed through the
CD28 costimulation receptor and provides an additive e¡ect
on the costimulation signal necessary for the optimal induc-
tion of IFN-Q and CD11a. Although anti-CD3 stimulation is
su⁄cient to upregulate CD40L expression, lyso-PC stimula-
tion could surrogate CD80 stimulation and augment CD40L
expression. However, we do not preclude the possibility that
lyso-PC transduces signals qualitatively di¡erent from those
provided by CD80 stimulation, because the presence of lyso-
PC stimulation downregulates VLA-4 expression which is up-
regulated by anti-CD3 and CD80 stimulation (data not
shown).
Second, the fact that lyso-PC augmented CD40L expression
and IFN-Q production implies two pathophysiological signi¢-
cances. (1) In in£amed tissue, where lyso-PC is synthesized by
secretory PLA2 [7] or by active oxygen [6], both CD40L and
IFN-Q activate monocytes and macrophages to produce reac-
tive nitrogen intermediates or various monokines [28] which
further propagate and sustain the in£ammatory reaction.
CD40L and IFN-Q also activate antigen presenting cells (den-
dritic cells) to upregulate class II molecules [29] and costimu-
lation molecules [29], which in turn further activate T cells in
an antigen speci¢c manner. In addition, since CD40 is neces-
sary for the generation of Th1-type memory T cells [30,31],
this lyso-PC e¡ect in the regulation of CD40L and IFN-Q
implies the possible involvement of lyso-PC in the selection
of Th1/Th2 response. (2) In atherosclerosis, T cells, migrating
to the intima where lyso-PC is synthesized from phosphatidyl-
choline or ox-LDL, potentially interact with macrophages to
enhance its monokine production or interact with CD40 pos-
itive SMC to induce chemokine production [10] or alter the
proliferation potency of SMC. Alternatively, CD40L positive
CD4+ T cells may contribute to the destabilization of plaque
and a ¢brous cap by inducing matrix degrading enzymes in
the SMC through CD40-CD40L interaction [11,12]. More-
over, the possible induction of Th1 cells by lyso-PC may
help the production of tissue factor and procoagulant activity
by macrophages [32].
Finally, lyso-PC increases the population of T cells express-
ing CD2 and CD11a (Fig. 4), of which the counter ligand
LFA-3 and ICAM-1 are expressed in endothelial cells, sug-
gesting that lyso-PC could regulate the interaction of T cells
with endothelial cells which are known to upregulate ICAM-1
by lyso-PC treatment [33]. Taken together, one can envisage
that lyso-PC could regulate the T cells’ interaction with endo-
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Fig. 4. A: Flow cytometric analysis of CD2 and CD11a (LFA-1)
expression in CD4+ T cells cocultured with Lwt, LCD32/neo, and
LCD32/CD80 for 90 h. Puri¢ed CD4+ T cells before stimulation
(a). Cocultured with LCD32/neo (b) and LCD32/CD80 (c) in the
medium containing anti-CD3 (1 Wg/ml). Lyso-PC (30 WM) was
added to the medium of coculture with LCD32/CD80 containing
anti-CD3 (1 Wg/ml) (d). B: The percentage of CD2bright/CD11apositive
cells (in region R2) in CD4+ T cells cocultured with indicated L
cells and anti-CD3 (1 Wg/ml) vs. dose of lyso-PC in the media
(**P6 0.05).
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thelial cells and thereby possibly regulate the migration of T
cells to the intima.
In summary, the present study shows that lyso-PC aug-
ments IFN-Q production and upregulates CD40L and
CD11a expression in CD4+ T cells. The overall e¡ects of
lyso-PC depend on the presence of concomitant activation
notably by CD3 and CD28 mediated stimuli. The fact that
lyso-PC can induce IFN-Q production and CD40L/CD11a ex-
pression in CD4+ T cells explains the novel pathway by which
lyso-PC exerts its proin£ammatory biological e¡ects, and also
suggests other roles played by lyso-PC in Th1/Th2 determina-
tion in the immune response and in the pathogenesis of athe-
rosclerosis.
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